Wire · opportunities
FDA approves baricitinib for adolescents with severe alopecia areata
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 September 2026 · Fusion42 review
The FDA has approved baricitinib (Olumiant) for adolescents aged 12 and older with severe alopecia areata, making it the first systemic oral treatment option for this age group in the US. Approval is based on positive phase 3 trial data showing substantial hair regrowth compared to placebo, with a safety profile consistent with adult use.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You gain a new opportunity to target pediatric alopecia areata with an FDA-approved oral therapy, expanding treatment access beyond adults. Paediatric dermatology founders should prepare to engage clinicians newly empowered to prescribe systemic options for adolescents.
◆ Coverage
1 source · 26 Sep 2026
◆ Related on Wire
◆ Topics